The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: The clinical conundrum from the perspective of haemophilia treaters

Haemophilia

Volumn 19, Issue 3, 2013, Pages 351-354

  Kessler, C M ^a   Iorio, A ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANTIBODY PRODUCTION; BLOOD COMPONENT THERAPY; CLINICAL DECISION MAKING; CLINICAL RESEARCH; HEMOPHILIA; HEMOPHILIA A; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; METHODOLOGY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN GLYCOSYLATION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BLOOD COAGULATION FACTOR INHIBITORS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; FACTOR VIII; GLYCOSYLATION; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 84876794924     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12149     Document Type: Note

References (12)

1. Gouw SC, van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
2. Enas GG, Enas NH, Spradlin CT, Wilson MG, Wiltse CG. Baseline comparability in clinical trials. Drug Inform J 1990; 24: 541-8.
3. Gouw SC, van den Berg HM, van der Bom JG, the PedNet and Rodin Study Group. Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: the Rodin study. In: The etiology of inhibitor development in children with severe hemophilia A. Thesis. Utrecht University. 2011. Chapter 7, page 167-94. Available at http://igitur-archive.library.uu.nl/dissertations/2011-1110-200501/gouw.pdf. Accessed March 4, 2013.
4. Pocock SJ, Lee RJ. Statistical problems in the reporting of clinical trials. N Engl J Med 1987; 317: 426-32.
5. Kreuz W, Gill JC, Rothchild C et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia. Thromb Haemost 2005; 93: 457-67.
6. Pahl S, Pavlova A, Driesen J, Müller J, Pötzsch B, Oldenburg J. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile. Haemophilia 2012. doi: 10.1111/hae.12076 [Epub ahead of print].
7. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta- analysis of prospective clinical studies J Thromb Haemost 2011; 9: 2180-92.
8. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
9. Tugwell P, Haynes B. Assessing claim of causation. In: Haynes B ed. Clinical Epidemiology How to do Clinical Practice Research. Lippincott Williams & Wilkins, 2006.
10. Gouw SC, Fijnvandraat K. Unraveling the genetics of inhibitors in hemophilia. Thromb Hemost 2013; 121: 1250-1.
11. Gouw SC, van den Berg M, Oldenburg J et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119: 2922-34.
12. European Medicines Agency. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/03/news_detail_001732.jsp&mid=WC0b01ac058004d5c1. Accessed September 3, 2013.